Timber Pharmaceuticals (NYSE:TMBR – Get Rating) had its price target lowered by HC Wainwright from $1.50 to $1.00 in a report published on Monday, MarketBeat.com reports. The firm currently has a buy rating on the stock. Timber Pharmaceuticals Price Performance TMBR opened at $0.12 on Monday. The firm has a market cap of $15.47 million, […]
